Santhera Pharmaceuticals Holding AG (SANN.XSWX) Financials
All currency values in CHF millions unless otherwise noted
Scroll
| Income Statement | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|
| Revenues | |||||
| Revenue | CHF 77 | CHF 39 | CHF 103 | CHF 7 | -CHF 2 |
| Cost of Revenue | CHF 62 | CHF 16 | CHF 3 | CHF 4 | CHF 4 |
| Gross Profit | CHF 15 | CHF 24 | CHF 100 | CHF 4 | -CHF 5 |
| Total Operating Expenses | CHF 53 | CHF 57 | CHF 49 | CHF 56 | CHF 52 |
| Operating Income | -CHF 38 | -CHF 33 | CHF 51 | -CHF 52 | -CHF 57 |
| Non-Operating | |||||
| Net Interest Expense | -CHF 12 | -CHF 8 | -CHF 21 | -CHF 20 | -CHF 16 |
| Income Tax Expense | CHF 0 | CHF 0 | CHF 0 | CHF 0 | CHF 1 |
| Net Income | |||||
| Net Income | -CHF 49 | -CHF 42 | CHF 55 | -CHF 71 | -CHF 56 |
| Per Share Data | |||||
| Revenue Per Share | CHF 5.93 | CHF 3.44 | CHF 9.78 | CHF 1.23 | -CHF 0.47 |
| EPS (Basic) | -CHF 3.78 | -CHF 3.69 | CHF 5.18 | -CHF 11.67 | -CHF 16.20 |
| EPS (Diluted) | -CHF 3.78 | -CHF 3.69 | CHF 5.01 | -CHF 11.67 | -CHF 16.20 |
| Shares Outstanding | 13.0M | 11.4M | 10.6M | 6.1M | 3.4M |
Santhera Pharmaceuticals Holding (SANN.XSWX) financials: revenue, profit and margins
Santhera Pharmaceuticals Holding (SANN.XSWX) generated about CHF 77 million in revenue and -CHF 49 million in net income (a -63.8% net margin) over the trailing twelve months, growing at roughly 117.8% a year. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Santhera Pharmaceuticals Holding's (SANN.XSWX) revenue?+
Santhera Pharmaceuticals Holding generated about CHF 77 million in revenue over the trailing twelve months. Revenue has grown at roughly 117.8% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Santhera Pharmaceuticals Holding profitable?+
Santhera Pharmaceuticals Holding reported about -CHF 49 million in net loss over the trailing twelve months, a net margin of roughly -63.8%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Santhera Pharmaceuticals Holding's profit margins?+
Santhera Pharmaceuticals Holding runs a gross margin of about 19.7%, an operating margin of about -48.7%, a net margin of about -63.8%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Santhera Pharmaceuticals Holding growing?+
Santhera Pharmaceuticals Holding's revenue has compounded at roughly 117.8% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside SANN.XSWX's margins and free cash flow. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.